# Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

> **NCT06532084** · PHASE2 · RECRUITING · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 88 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Myelodysplastic Syndromes
- Chronic Myeloid Leukemia
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT06532084
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2027-05
- **Final completion:** 2028-05
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532084, "Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06532084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*